TruScreen Receives CFDA Approval for its Second Generation

NZX and Media Release 4 December, 2017
NZX Limited
WELLINGTON

TruScreen Receives CFDA Approval for its Second Generation Device in China

Cervical cancer screening technology company, TruScreen Limited (NZAX: TRU) is pleased to advise
that the China Food and Drug Administration (CFDA) have issued its formal certificate of approval
permitting the commercial supply and sale in China of the new upgraded TruScreen2 cervical cancer
screening device.
TruScreen CEO Mr Martin Dillon said “CFDA registration is, by global standards, an extremely
rigorous validation process which certifies the engineering, quality and efficacy of our product for
use in our major market , China. The company has been steadily building up its inventories in
anticipation of receiving the registration and will now commence export sales of the new device to
China as soon as practicably possible.”

ENDS
For more information visit www.truscreen.com or contact:
Martin Dillon
TruScreen Chief Executive Officer
Email: martindillon@truscreen.com
Media Liaison
Jackie Ellis
Email: jackie@ellisandco.co.nz
Phone: +64 27 246 2505

About TruScreen:
TruScreen’s real time cervical cancer technology
utilises a digital wand which is placed on the
surface of the cervix to measure electrical and
optical signals from the surrounding tissue. A
sophisticated proprietary algorithm framework
distinguishes between normal and abnormal
(cancerous and precancerous) tissue to identify
precancerous change, or cervical intraepithelial
neoplasia (CIN). A Single Use Sensor (SUS) is used
for each patient to protect against cross-infection.